These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26420428)

  • 21. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.
    Young G; Wang K; He J; Otto G; Hawryluk M; Zwirco Z; Brennan T; Nahas M; Donahue A; Yelensky R; Lipson D; Sheehan CE; Boguniewicz AB; Stephens PJ; Miller VA; Ross JS
    Cancer Cytopathol; 2013 Dec; 121(12):688-94. PubMed ID: 23893923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.
    Pfarr N; Stenzinger A; Penzel R; Warth A; Dienemann H; Schirmacher P; Weichert W; Endris V
    Genes Chromosomes Cancer; 2016 Jan; 55(1):30-44. PubMed ID: 26394895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next-Generation Sequencing Approach to Non-Small Cell Lung Carcinoma Yields More Actionable Alterations.
    Mehrad M; Roy S; Bittar HT; Dacic S
    Arch Pathol Lab Med; 2018 Mar; 142(3):353-357. PubMed ID: 29219616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hot spot mutations in Finnish non-small cell lung cancers.
    Mäki-Nevala S; Sarhadi VK; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuuttila A; Knuutila S
    Lung Cancer; 2016 Sep; 99():102-10. PubMed ID: 27565922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lung cancer molecular testing, what role for Next Generation Sequencing and circulating tumor DNA].
    Pécuchet N; Legras A; Laurent-Puig P; Blons H
    Ann Pathol; 2016 Jan; 36(1):80-93. PubMed ID: 26803564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genome analysis of peeling archival cytology samples detects driver mutations in lung cancer.
    Kunimasa K; Hirotsu Y; Amemiya K; Nagakubo Y; Goto T; Miyashita Y; Kakizaki Y; Tsutsui T; Otake S; Kobayashi H; Higuchi R; Inomata K; Kumagai T; Mochizuki H; Nakamura H; Nakatsuka SI; Nishino K; Imamura F; Kumagai T; Oyama T; Omata M
    Cancer Med; 2020 Jul; 9(13):4501-4511. PubMed ID: 32351019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
    Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
    Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.
    Kou T; Kanai M; Yamamoto Y; Kamada M; Nakatsui M; Sakuma T; Mochizuki H; Hiroshima A; Sugiyama A; Nakamura E; Miyake H; Minamiguchi S; Takaori K; Matsumoto S; Haga H; Seno H; Kosugi S; Okuno Y; Muto M
    Cancer Sci; 2017 Jul; 108(7):1440-1446. PubMed ID: 28440963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical next-generation sequencing in patients with non-small cell lung cancer.
    Hagemann IS; Devarakonda S; Lockwood CM; Spencer DH; Guebert K; Bredemeyer AJ; Al-Kateb H; Nguyen TT; Duncavage EJ; Cottrell CE; Kulkarni S; Nagarajan R; Seibert K; Baggstrom M; Waqar SN; Pfeifer JD; Morgensztern D; Govindan R
    Cancer; 2015 Feb; 121(4):631-9. PubMed ID: 25345567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients.
    Liu L; Liu J; Shao D; Deng Q; Tang H; Liu Z; Chen X; Guo F; Lin Y; Mao M; Kristiansen K; Ye M; He J
    Cancer Sci; 2017 Dec; 108(12):2487-2494. PubMed ID: 28949084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain.
    Zazo S; Pérez-Buira S; Carvajal N; Plaza-Sánchez J; Manso R; Pérez-González N; Dominguez C; Prieto-Potin I; Rubio J; Dómine M; Lozano V; Mohedano P; Carcedo D; Carias R; Rojo F
    Cancer Med; 2024 Feb; 13(3):e6827. PubMed ID: 38213074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
    Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
    Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.
    Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X
    Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
    Chen L; Chen M; Lin J; Chen X; Yu X; Chen Z; Jin L
    Int J Clin Exp Pathol; 2020; 13(3):525-535. PubMed ID: 32269691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing.
    Isaka M; Serizawa M; Kenmotsu H; Koh Y; Takahashi S; Maniwa T; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Endo M; Abe M; Hayashi I; Nakajima T; Yamamoto N; Takahashi T; Ohde Y
    Clin Lung Cancer; 2017 Sep; 18(5):519-526.e1. PubMed ID: 28057436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels.
    Poirot B; Doucet L; Benhenda S; Champ J; Meignin V; Lehmann-Che J
    J Thorac Oncol; 2017 Oct; 12(10):1582-1587. PubMed ID: 28779874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of multiple types of cancer driver mutations using targeted RNA sequencing in non-small cell lung cancer.
    Ju S; Cui Z; Hong Y; Wang X; Mu W; Xie Z; Zeng X; Su L; Lin X; Zhang Z; Zhang Q; Song X; You S; Chen R; Chen W; Xu C; Zhao J
    Cancer; 2023 Aug; 129(15):2422-2430. PubMed ID: 37096747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
    Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S
    Anticancer Res; 2018 Oct; 38(10):5627-5634. PubMed ID: 30275180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.